Comparative Pharmacology
Head-to-head clinical analysis: ONGLYZA versus SITAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONGLYZA versus SITAGLIPTIN.
ONGLYZA vs SITAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin (GLP-1 and GIP) levels by preventing their degradation, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
2.5 mg or 5 mg orally once daily
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Clinical Note
moderateSitagliptin + Gatifloxacin
"Sitagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSitagliptin + Rosoxacin
"Sitagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSitagliptin + Levofloxacin
"Sitagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSitagliptin + Trovafloxacin
"Sitagliptin may increase the hypoglycemic activities of Trovafloxacin."
12.4 hours; supports once-daily dosing with effect ≥24 h due to sustained DPP-4 inhibition.
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Renal: ~87% unchanged in urine (active tubular secretion); fecal: <13% (metabolites).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor